Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1DNA Repair-Deficiency Disorders 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 262Specimen Handling 253pembrolizumab 230Cyclophosphamide 216Radiotherapy 204Nivolumab 168Cisplatin 161Carboplatin 145Biopsy 144Radiosurgery 128fludarabine 123Blood Specimen Collection 116Gemcitabine 111Paclitaxel 107Surveys and Questionnaires 106Standard of Care 102venetoclax 94Dexamethasone 93Bevacizumab 92Radiation 87Rituximab 81Capecitabine 80Cytarabine 79Oxaliplatin 77Drug Therapy 75Doxorubicin 75Ipilimumab 73durvalumab 70fludarabine phosphate 69atezolizumab 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × omega-N-Methylarginine × 90 days × Clear all
NCT05660083 2026-06-04

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

The Methodist Hospital Research Institute

Phase 2 Recruiting
36 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

Phase 1 Completed
12 enrolled 15 charts
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡